FDA Extends Action Date for Additional sBLA in Ipilimumab-Refractory Advanced Melanoma

The FINANCIAL -- Merck, known as MSD outside the United States and Canada, on August 18 announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy. The FINANCIAL -- Merck, known as MSD outside the United States and Canada, on August 18 announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy. Merck is seeking approval for KEYTRUDA, at the currently approved dose of 2 mg/kg every » The FINANCIAL Pharmacy

Related Keywords

United States ,Canada ,American ,Rogerm Perlmutter , ,Merck Research Laboratories ,Drug Administration ,American Associated For Cancer Research ,Biologics License Application ,Priority Review ,Merck Research ,Cancer Research ,Annual Meeting ,New England Journal ,Pharmacy ,